Compare CETX & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CETX | CVKD |
|---|---|---|
| Founded | 1998 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 17.0M |
| IPO Year | 1998 | 2023 |
| Metric | CETX | CVKD |
|---|---|---|
| Price | $1.79 | $7.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 8.6M | 53.5K |
| Earning Date | 02-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $76,488,088.00 | N/A |
| Revenue This Year | $20.41 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.39 | N/A |
| 52 Week Low | $1.74 | $6.42 |
| 52 Week High | $42.60 | $22.90 |
| Indicator | CETX | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 46.70 |
| Support Level | $1.74 | $7.07 |
| Resistance Level | $1.95 | $8.21 |
| Average True Range (ATR) | 0.28 | 0.57 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 1.91 | 45.11 |
Cemtrex Inc is a multi-industry technology company. It has expanded into a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security systems. The company's operating segment includes the Security segment and the Industrial Services segment. The security segment provides end-to-end security to all industrial, corporate, and governmental security via its owned subsidiary, Vicon. Whereas the AIS part Industrial Service Segment is expertise services for rigging, millwrighting, in-plant maintenance, equipment erection, relocation, and disassembly to diversified customers. It generates maximum revenue from the Industrial Service Segment, and from the USA. It also operates UK, USA, and Other.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.